Close Menu

Tech Review reports on a new study from the Journal of Clinical Oncology that provides a link between personalized medicine and better health outcomes. For the study, oncologist Lecia Sequist genetically screened patients' lung cancers and then administered a drug tailored for that type of tumor — and those patients did better than the average chemotherapy outcomes. In particular, the study looked at AstraZeneca's Iressa, an EGFR inhibitor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.